Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Not yet recruiting Phase 1 Interventional Accepts healthy volunteers

A Study of LY3945262 in Healthy Participants

ClinicalTrials.gov ID: NCT07943091

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT07943091. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 12:19 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1, Randomized, Investigator- and Participant-Blinded, Placebo-Controlled, Single- and Multiple-Ascending Dose Study to Characterize the Safety, Tolerability, and Pharmacokinetics of LY3945262 and an Open Label, Randomized, Fixed Sequence, Relative Bioavailability Study of LY3945262 in Healthy Participants

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The main purpose of this study is to evaluate how well LY3945262 is tolerated, what side effects may occur, and how much LY3945262 gets into the bloodstream and how long it takes the body to remove it in healthy participants. The study will also compare how LY3945262 gets into the bloodstream when administered in different ways. This study will last approximately 8 weeks and may include up to 4 visits.

Study identification

NCT ID
NCT07943091
Recruitment status
Not yet recruiting
Study type
Interventional
Phase
Phase 1
Lead sponsor
Eli Lilly and Company
Industry
Enrollment
116 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years to 65 Years
Sex
All
Healthy volunteers
Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 2026 (Estimated)
Primary completion
Sep 2027 (Estimated)
Completion
Sep 2027 (Estimated)
Last update posted
Nov 17, 2026

2026 – 2027

United States locations

U.S. sites
2
U.S. states
2
U.S. cities
2
Facility City State ZIP Site status
Collaborative Neuroscience Network - CNS Los Alamitos California 90720 —
ICON Early Phase Services San Antonio Texas 78232 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT07943091, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 17, 2026 · Synced Nov 19, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.